drugset / Trial / NCT06289504

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

NCT06289504

Phase 1 Completed 34 enrolled Novo Nordisk A/S
RandomizedSequentialOpen-labelTreatment

Summary

This study will look at how CagriSema affects the blood levels of atorvastatin and warfarin. The study will look at the levels of warfarin and atorvastatin in the blood before the participant starts taking CagriSema and if this changes after the participant has taken CagriSema. The study will also investigate the effect of warfarin before and after the participant takes CagriSema and assess if the injection site affects the level of CagriSema in the blood. The study will last for about 8 months.

Timeline

Start
2024-02-27
Primary completion
2024-10-16
Completion
2024-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule Oral
Subject Cagrilintide Protein / enzyme biologic Subcutaneous
Subject Semaglutide Peptide Subcutaneous
Subject Warfarin Small molecule Oral

Indications